FORTRESS BIOTECH.PRF.A 25
Research FORTRESS BIOTECH.PRF.A 25 (CNB0) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerCNB0
- ExchangeF
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Financial periodQ4 2025
- RevenueEUR 16.08M
- Net income-EUR 3.94M
- Free cash flow-EUR 12.54M
- Gross margin66.2%
About FORTRESS BIOTECH.PRF.A 25
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne;
Frequently asked questions
What does FORTRESS BIOTECH.PRF.A 25 do?
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea;